FDA approval weighs advantages, harms of the Alzheimer’s drug lecanemab
Federal drug regulators will determine by July 6 whether or not to grant the primary conventional approval to an amyloid-busting drug to deal with Alzheimer’s illness. On June 9, the Meals and Drug Administration’s advisory panel of specialists endorsed the drug, lecanemab, as efficient – whereas not voting on the thornier query of the right
Read More